Banque Cantonale Vaudoise Makes New Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Banque Cantonale Vaudoise acquired a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 5,560 shares of the biopharmaceutical company's stock, valued at approximately $1,529,000.

Several other large investors have also modified their holdings of ALNY. Allspring Global Investments Holdings LLC lifted its stake in Alnylam Pharmaceuticals by 572.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 143 shares during the last quarter. Ashton Thomas Private Wealth LLC acquired a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at $26,000. Huntington National Bank raised its position in Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 45 shares during the last quarter. Hollencrest Capital Management acquired a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth $29,000. Finally, Altitude Crest Partners Inc. acquired a new stake in Alnylam Pharmaceuticals during the 1st quarter worth $30,000. Institutional investors and hedge funds own 92.97% of the company's stock.

Alnylam Pharmaceuticals Trading Up 6.2 %

Shares of ALNY opened at $248.79 on Thursday. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $304.39. The stock has a market cap of $32.09 billion, a price-to-earnings ratio of -94.96 and a beta of 0.39. The firm has a 50 day simple moving average of $273.83 and a 200-day simple moving average of $236.76.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. The firm's revenue was down 33.3% on a year-over-year basis. During the same period last year, the business posted $1.15 earnings per share. Equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.22 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $220.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, October 11th. Canaccord Genuity Group upped their price objective on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a "buy" rating in a research note on Friday, November 1st. HC Wainwright reiterated a "buy" rating and issued a $400.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday. Piper Sandler reiterated an "overweight" rating and set a $296.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday. Finally, Raymond James boosted their target price on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an "outperform" rating in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and nineteen have issued a buy rating to the company's stock. According to MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $298.09.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.